Alessandro Fanzani
Overview
Explore the profile of Alessandro Fanzani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
5667
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pozzo E, Yedigaryan L, Giarratana N, Wang C, Garrido G, Degreef E, et al.
Cell Rep
. 2025 Jan;
44(1):115171.
PMID: 39799567
Rhabdomyosarcoma (RMS), the most common pediatric soft tissue sarcoma, arises in skeletal muscle and remains in an undifferentiated state due to transcriptional and post-transcriptional regulators. Among its subtypes, fusion-negative RMS...
2.
Codenotti S, Asperti M, Poli M, Lorenzi L, Pietrantoni A, Cassandri M, et al.
Mol Metab
. 2024 Dec;
92:102085.
PMID: 39706565
Objective: The aim of the present study was to investigate the effects of targeting the mevalonate pathway (MVP) in rhabdomyosarcoma (RMS), a soft tissue tumor with a prevalence in young...
3.
Salucci S, Bavelloni A, Versari I, Burattini S, Bavelloni F, Gobbi P, et al.
Biomolecules
. 2024 Sep;
14(9).
PMID: 39334946
Rhabdomyosarcoma (RMS), the most common form of sarcoma typical of pediatric age, arises from the malignant transformation of the mesenchymal precursors that fail to differentiate into skeletal muscle cells. Here,...
4.
Cassandri M, Porrazzo A, Pomella S, Noce B, Zwergel C, Aiello F, et al.
Cell Death Discov
. 2024 Aug;
10(1):351.
PMID: 39107280
Radiotherapy (RT) plays a critical role in the management of rhabdomyosarcoma (RMS), the prevalent soft tissue sarcoma in childhood. The high risk PAX3-FOXO1 fusion-positive subtype (FP-RMS) is often resistant to...
5.
Corsetti G, Romano C, Codenotti S, Giugno L, Pasini E, Fanzani A, et al.
Cells
. 2024 Jul;
13(14.
PMID: 39056792
Cancer cells require substantial amounts of energy and substrates for their metabolic hyperactivity, enabling the synthesis of new cells at the expense of healthy ones. Preliminary in vitro data suggest...
6.
Codenotti S, Sandrini L, Mandracchia D, Lorenzi L, Corsetti G, Poli M, et al.
Cancers (Basel)
. 2024 Mar;
16(5).
PMID: 38473215
Identifying the molecular mechanisms underlying radioresistance is a priority for the treatment of RMS, a myogenic tumor accounting for approximately 50% of all pediatric soft tissue sarcomas. We found that...
7.
Zizioli D, Codenotti S, Benaglia G, Manzoni M, Massardi E, Fanzani A, et al.
Int J Mol Sci
. 2023 Sep;
24(17).
PMID: 37686385
Sialidases remove terminal sialic acids residues from the non-reducing ends of glycoconjugates. They have been recognized as catabolic enzymes that work within different subcellular compartments and can ensure the proper...
8.
Asperti M, Cantamessa L, Gryzik M, Bugatti M, Codenotti S, Denardo A, et al.
Clin Exp Med
. 2023 Feb;
23(6):2487-2502.
PMID: 36764998
Rhabdomyosarcoma (RMS) is an aggressive rare neoplasm that derives from mesenchymal cells, which frequently develops resistance to the current therapies and the formation of metastases. Thus, new therapies are needed....
9.
Perrone C, Pomella S, Cassandri M, Pezzella M, Giuliani S, Gasperi T, et al.
Front Cell Dev Biol
. 2023 Feb;
11:1061570.
PMID: 36755974
Rhabdomyosarcoma (RMS) is a pediatric myogenic soft tissue sarcoma that includes fusion-positive (FP) and fusion-negative (FN) molecular subtypes. FP-RMS expresses PAX3-FOXO1 fusion protein and often shows dismal prognosis. FN-RMS shows...
10.
Vaccaro S, Rossetti A, Porrazzo A, Camero S, Cassandri M, Pomella S, et al.
Front Pharmacol
. 2022 Dec;
13:1071176.
PMID: 36532747
Treatment of rhabdomyosarcoma (RMS), the most common a soft tissue sarcoma in childhood, provides intensive multimodal therapy, with radiotherapy (RT) playing a critical role for local tumor control. However, since...